EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC 4.0

Nanoformulations as a strategy to overcome the delivery limitations of cannabinoids

T Srinivasa Reddy, Roby Zomer, Nitin Mantri iD

Phytotherapy Research · 2023-04 · 37 (4) · 1526-1538

DOI: 10.1002/ptr.7742 ↗

At a glance

Übersichtsarbeit in Phytotherapy Research, published online on 2023-02-07. Written by T Srinivasa Reddy and 2 co-authors. Institution: The Pangenomics Group, Biosciences and Food Technology, School of Science, RMIT University, Melbourne, Victoria, Australia. Major MEDLINE topics: Cannabinoids, Cannabidiol. Cited 71 times so far (Crossref); 113 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: MGC Pharmaceuticals Limited.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Medical cannabis has received significant interest in recent years due to its promising benefits in the management of pain, anxiety, depression and neurological and movement disorders. Specifically, the major phytocannabinoids derived from the cannabis plant such as (−) trans‐Δ 9 ‐tetrahydrocannabinol (THC) and cannabidiol (CBD), have been shown to be responsible for the pharmacological and therapeutic properties. Recently, these phytocannabinoids have also attracted special attention in cancer treatment due to their well‐known palliative benefits in chemotherapy‐induced nausea, vomiting, pain and loss of appetite along with their anticancer activities. Despite the enormous pharmacological benefits, the low aqueous solubility, high instability (susceptibility to extensive first pass metabolism) and poor systemic bioavailability restrict their utilization at clinical perspective. Therefore, drug delivery strategies based on nanotechnology are emerging to improve pharmacokinetic profile and bioavailability of cannabinoids as well as enhance their targeted delivery. Here, we critically review the nano‐formulation systems engineered for overcoming the delivery limitations of native phytocannabinoids including polymeric and lipid‐based nanoparticles (lipid nano capsules (LNCs), nanostructured lipid carriers (NLCs), nanoemulsions (NE) and self‐emulsifying drug delivery systems (SEDDS)), ethosomes and cyclodextrins as well as their therapeutic applications.

Subjects

MeSH terms (MEDLINE)

CannabinoidsCannabidiolHumansDronabinolPainLipids

Author keywords

cannabidiolcannabinoidsdrug deliverymedical cannabisnanoformulationstetrahydrocannabinol

Substances

CannabinoidsCannabidiolDronabinolLipids

Authors and institutions

  • The Pangenomics Group, Biosciences and Food Technology, School of Science, RMIT University, Melbourne, Victoria, Australia.
  • MGC Pharmaceuticals Limited, West Perth, Western Australia, Australia.
  • The UWA Institute of Agriculture, The University of Western Australia, Perth, Western Australia, Australia.

ORCID profiles: Nitin Mantri

Funding

  • MGC Pharmaceuticals Limited

Cite

APA

Reddy, T. S., Zomer, R., & Mantri, N. (2023). Nanoformulations as a strategy to overcome the delivery limitations of cannabinoids. Phytotherapy Research, 37(4), 1526-1538. https://doi.org/10.1002/ptr.7742

Vancouver

Reddy TS, Zomer R, Mantri N. Nanoformulations as a strategy to overcome the delivery limitations of cannabinoids. Phytotherapy Research. 2023;37(4):1526-1538. doi:10.1002/ptr.7742

BibTeX
@article{Reddy2023,
  author = {Reddy, T Srinivasa and Zomer, Roby and Mantri, Nitin},
  title = {Nanoformulations as a strategy to overcome the delivery limitations of cannabinoids},
  journal = {Phytotherapy Research},
  year = {2023},
  volume = {37},
  number = {4},
  pages = {1526--1538},
  doi = {10.1002/ptr.7742}
}
Start for free →